Abstract: A system for generating electrical energy from the wave motion of the sea is provided with electrical-energy generating means for exploiting the wave motion of the sea in order to generate electrical energy. A floating body is provided with equipment designed to regulate the frequency of the resonance peak of the system.

Abstract: Compositions and methods for regulating the blood coagulation pathway are disclosed. More particularly, the present disclosure relates to thrombin-thrombomodulin fusion proteins and their use as blood anticoagulants and for treating sepsis.

Abstract: A system for generating electrical energy from the wave motion of the sea is provided with electrical-energy generating means for exploiting the wave motion of the sea in order to generate electrical energy. A floating body is provided with equipment designed to regulate the frequency of the resonance peak of the system.

Abstract: Compositions and methods for regulating the blood coagulation pathway are disclosed. More particularly, the present disclosure relates to thrombin-thrombomodulin fusion proteins, vectors, host cells and methods for preparing the thrombin-thrombomodulin fusion proteins. The present disclosure further relates to methods for measuring protein C in plasma and kits for measuring protein C in plasma.

Abstract: Compositions and methods for regulating the blood coagulation pathway are disclosed. More particularly, the present disclosure relates to thrombin-thrombomodulin fusion proteins and their use as blood anticoagulants and for treating sepsis.

Abstract: Compositions and methods for regulating the blood coagulation pathway are disclosed. More particularly, the present disclosure relates to thrombin-thrombomodulin fusion proteins, vectors, host cells and methods for preparing the thrombin-thrombomodulin fusion proteins. The present disclosure further relates to methods for measuring protein C in plasma and kits for measuring protein C in plasma.

Abstract: A recombinant serine protease precursor that auto-activates in an aqueous buffer to form a mature active enzyme is disclosed. A contemplated precursor contains 1 to about 10 heterologous amino acid residues that function to enhance by at least ten-fold the room temperature rate of auto-lytic bond cleavage to form the active enzyme relative to the auto-lytic cleavage rate of the native enzyme precursor when each precursor is dispersed in an aqueous buffer at an optimal pH value for the proteolytic activity of the protease. Illustrative active enzymes include serine proteases such as thrombin and protein C. A method of preparing and using an enzyme precursor is also disclosed.

Abstract: One aspect of the invention contemplates a mutant E-WE thrombin precursor that contains the SEQ ID NO:1 amino acid residue sequence. Another aspect contemplates a thrombin precursor that contains the amino acid residue sequence Asp/Glu-Gly-Arg at positions 325, 326 and 327 based on the preprothrombin sequence. A third aspect contemplates a thrombin precursor that contains the SEQ ID NO:1 amino acid residue sequence as well as the amino acid residue sequence Asp/Glu Gly Arg at positions 325, 326 and 327 based on the preprothrombin sequence. Also contemplated is a composition that contains an effective amount of mutant thrombin dissolved or dispersed in a pharmaceutically acceptable carrier. A method is also disclosed for enhancing treating and preventing thrombosis in a mammal in need using that composition.

Abstract: A recombinant serine protease precursor that auto-activates in an aqueous buffer to form a mature active enzyme is disclosed. A contemplated precursor contains 1 to about 10 heterologous amino acid residues that function to enhance by at least ten-fold the room temperature rate of auto-lytic bond cleavage to form the active enzyme relative to the auto-lytic cleavage rate of the native enzyme precursor when each precursor is dispersed in an aqueous buffer at an optimal pH value for the proteolytic activity of the protease. Illustrative active enzymes include serine proteases such as thrombin and protein C. A method of preparing and using an enzyme precursor is also disclosed.

Abstract: One aspect of the invention contemplates a mutant E-WE thrombin precursor that contains the SEQ ID NO:1 amino acid residue sequence. Another aspect contemplates a thrombin precursor that contains the amino acid residue sequence Asp/Glu-Gly-Arg at positions 325, 326 and 327 based on the preprothrombin sequence. A third aspect contemplates a thrombin precursor that contains the SEQ ID NO:1 amino acid residue sequence as well as the amino acid residue sequence Asp/Glu Gly Arg at positions 325, 326 and 327 based on the preprothrombin sequence. Also contemplated is a composition that contains an effective amount of mutant thrombin dissolved or dispersed in a pharmaceutically acceptable carrier. A method is also disclosed for enhancing treating and preventing thrombosis in a mammal in need using that composition.